Continuing Coverage: NanoViricides, Inc. (NYSE: NNVC) Makes New February High–You Watching Yet?

*Sponsored Continuing Coverage! NanoViricides, Inc. (NYSE: NNVC) Gets Continued Coverage as Our Next Potential Breakout Idea For Friday Morning! (2/21/2025) NanoViricides, Inc. (NYSE: NNVC) comes backed with several  potential catalysts including: Inside just 12 sessions, NanoViricides, Inc. (NYSE: NNVC) recently moved approximately 45%. NanoViricides, Inc. (NYSE: NNVC) has surpassed key moving averages, suggesting positive market sentiment, and the potential for continued momentum.  With a market cap under $20M and fewer than 14M shares listed in the float, NanoViricides, Inc. (NYSE: NNVC) is structured in a way that has historically fueled explosive growth potential.  NanoViricides, Inc. (NYSE: NNVC) is developing NV-387, with preclinical studies showing remarkable potential as it progresses to Phase 2 trials. The global anti-vi-ral treatment market is valued at over $10B, and NanoViricides, Inc. (NYSE: NNVC) is positioning itself in this market with its innovative solutions. NanoViricides, Inc. (NYSE: NNVC) is advancing multiple clinical programs, including Phase 2 trials for NV-387, targeting vi-ral respiratory infections with plans for FDA submission, which could signal strong growth potential. Keep Reading to See Why We Have All Eyes on NanoViricides, Inc. (NYSE: NNVC) For This Morning… February 21, 2025 Dear Reader, Have you added NanoViricides, Inc. (NYSE: NNVC) to your radar yet? After (NNVC) reached $1.55 yesterday, making a new February high, we’re continuing our coverage on this profile. In fact, in yesterday’s afternoon session, (NNVC) was triggering 17 Bullish Signals, including the Momentum Indicator, on TradingView’s technical analysis tool, using the 5 minute time-frame. You see, Biotech and Pharma offer unparalleled potential, where a single breakthrough can turn an under-the-radar company into a market leader. Some innovations don’t just shift the needle—they change the game. That’s where NanoViricides, Inc. (NYSE: NNVC) comes in. Today, the American Medical Association (AMA) issued an urgent update on the ongoing flu season, which is now the worst in over a decade.  With over 29 Mln cases reported, hospitalizations and deaths are surging, and pediatric deaths have reached 68.  Some flu cases are resulting in severe neurological complications, highlighting the gravity of this season. Just days ago, a newly discovered virus in the U.S.—the Camp Hill virus—was linked to the deadly Nipah virus, sparking fears of a potential global pan-dem-ic.  This adds to the growing concern about emerging vi-ral threats. The CDC’s latest data raises concerns about a mutating influenza virus transmitted by birds. This virus has already caused several hospitalizations and may be spreading undetected among humans.  The CDC has identified farmworkers as high-risk individuals due to their exposure to infected animals, and the virus has been found in cattle and pigs. If left unchecked, this hybridization of animal and human flu strains could lead to a new virus capable of human-to-human transmission, potentially triggering a pan-dem-ic. With flu-related hospitalizations and deaths continuing to rise, especially among children, the CDC is urging vigilance and preparation.  This flu season is one of the most severe in recent history, and experts are monitoring the situation closely. The next big breakthrough might come from companies you’ve never heard of—pay attention before the window closes. NanoViricides, Inc. (NYSE: NNVC) is at the forefront of anti-vi-ral technology, developing cutting-edge solutions for some of the world’s toughest vi-ral threats.  Their innovative approach positions them as an emerging player in the fight against infectious diseases. NanoViricides, Inc. (NYSE: NNVC) Moves Approx. 45% in 12 Sessions, Now Trending Above Key Moving Averages… NanoViricides, Inc. (NYSE: NNVC) has recently moved approximately 45% inside of 12 sessions, from $1.03 on 1/28/2025 to $1.50 on 2/12/2025. Early yesterday, (NNVC) reached $1.38, trending above or near several key moving averages including: 5-Day: 1.35 20-Day: 1.2175 50-Day: 1.3388 100-Day: 1.3789 Year-to-Date: 1.2578 And with the 200-Day moving average currently at $1.6757, we have all eyes on NanoViricides, Inc. (NYSE: NNVC) right now. With a market cap under $20M and fewer than 14M shares listed in the float, available to the public, NanoViricides, Inc. (NYSE: NNVC) is structured in a way that has historically fueled explosive growth potential.  This relatively low number of shares in the float can amplify movements, making it an even more interesting company to watch. Keep reading to see why NanoViricides, Inc. (NYSE: NNVC) is topping our watchlist this morning… NanoViricides, Inc. (NYSE: NNVC) Reveals Fiscal Health and Breakthrough Potential in Latest Quarterly Report… NanoViricides, Inc. (NYSE: NNVC) has announced the successful filing of its Quarterly Report for the period ending December 31, 2024, today, February 19, 2025.  The report highlights the company’s solid financial position with a cash balance of approximately $3.96M and substantial assets of $7.17M, including its state-of-the-art cGMP-capable manufacturing and R&D facility in Shelton, CT.  These accomplishments, along with its ongoing commitment to regulatory strategy and clinical programs, could help position NanoViricides, Inc. (NYSE: NNVC) as an emerging player focused on addressing global health threats with innovative anti-vi-ral solutions.  With continued progress in its clinical programs, NanoViricides, Inc. (NYSE: NNVC) is on track to lead in the development of breakthrough anti-vi-ral therapies. NanoViricides Speeds Up Efforts Against Emerging Vi-ral Threat with Groundbreaking NV-387 Treatment A new vir-al out-break has been declared a Public Health Emergency of International Concern by the World Health Organization.  A concerning variant, particularly dangerous for children, has emerged with heightened transmissibility and lethality.  Despite global attention, no approved treatment exists for this new vir-us, especially as it spreads beyond its origin. NanoViricides, Inc. (NYSE: NNVC) is working on an innovative solution, accelerating efforts to fight this out-break with its dr-ug, NV-387.  Preclinical studies show remarkable potential, and Phase 2 trials are on the horizon, focusing on patients affected by this new vir-us. NanoViricides Steps Up to Tackle the World’s Evolving Vi-ral Threats In addition to combating the current out-break, NanoViricides, Inc. (NYSE: NNVC) is addressing another looming threat: the rapidly mutating influenza vir-us transmitted by birds. The World Health Organization has raised concerns over genetic mutations in the vir-us that may render existing treatments ineffective.  Unlike conventional anti-vir-al dr-ugs that are vulnerable to mutations, NV-387 mimics host-side features the vir-us cannot alter, ensuring continued effectiveness even as the vir-us evolves. NV-387 has demonstrated broad-spectrum anti-vir-al properties, effective against vir-uses like influenza, RSV, and even orthopox vir-uses.  Early animal studies indicate superior performance over existing treatments like Tamiflu, making it a promising tool for tackling a wide range of vir-al diseases. NanoViricides Advances NV-387 to Phase 2 Trials, Preparing for  Critical FDA Submission NanoViricides, Inc. (NYSE: NNVC) is set to begin Phase 2 clinical trials for NV-387, focusing on treating patients infected by the new vir-us variant and expanding its use to respiratory vir-uses.  The trials will start with dose escalation, with results expected to inform the next steps toward FDA submission. With no current approved treatments for the new vir-al variant or the evolving H5N1 strain, NanoViricides, Inc. (NYSE: NNVC)’s research is more critical than ever.  The company is poised to be a key player in the fight against these global health threats, with NV-387 offering a potential cure and broad protection against emerging pathogens. With a market potential exceeding $10B, NanoViricides, Inc. (NYSE: NNVC) is advancing rapidly in the biotech space with groundbreaking anti-vir-al treatments.  The company is uniquely positioned for growth with its cutting-edge nanoviricide® technology, promising an impactful future in global health. NanoViricides, Inc. (NYSE: NNVC) Highlights  FDA Progress: Moving toward FDA submission with positive feedback on its NV-HHV-101 dr-ug candidate for herpes vir-uses. Innovative Technology: Nanoviricides can target vir-uses even as they mutate, offering broad protection against Vir-al infections. Manufacturing Facility: The company owns a cGMP-certified facility in Shelton, CT, allowing it to produce dr-ugs in-house, saving time and costs. HerpeCide™ Program: Focused on treating shingles, cold sores, and genital ulcers, with an estimated market size exceeding $10B. Diverse Pipeline: dr-ugs in development for influenza, HIV, Dengue, and Ebola with promising animal model results. Strong IP Portfolio: Exclusive patents for its TheraCour® technology, securing competitive market space. NanoViricides, Inc. (NYSE: NNVC) is positioned for growth with its breakthrough technology, broad pipeline, and in-house manufacturing, making it a key player in the fight against Vir-al diseases. 7 Reasons Why NanoViricides, Inc. (NYSE: NNVC) Topping Our  Watchlist This Morning… 1. Recent Market Recognition: Inside just 12 sessions, NanoViricides, Inc. (NYSE: NNVC) recently moved approximately 45%. 2. Surpassing Key Technical Levels: NanoViricides, Inc. (NYSE: NNVC) has surpassed key moving averages, including the 5-Day, 20-Day, 50-Day, and 100-Day, suggesting positive market sentiment and momentum. 3. Low Float: With a market cap under $20M and fewer than 14M shares listed in the float, NanoViricides, Inc. (NYSE: NNVC) is structured in a way that has historically fueled explosive growth potential.  4. Breakthrough Technology: NanoViricides, Inc. (NYSE: NNVC) is developing NV-387, a broad-spectrum anti-vi-ral agent designed to combat emerging vi-ral threats, including those that are rapidly mutating.  5. Successful Phase 1 Trial: NV-387 has already completed a successful Phase 1 clinical trial with no reported adverse events, providing strong evidence of its safety and setting the stage for the upcoming Phase 2 trials. 6. Market Potential: The global market for anti-vi-ral treatments is valued at over $10B, and NanoViricides, Inc. (NYSE: NNVC) is positioning itself in this market with its innovative solutions. 7. Strong Clinical Pipeline: The company is advancing multiple clinical programs, including Phase 2 trials for NV-387 to treat vi-ral respiratory infections, including those transmitted by birds and monkeys, with a clear regulatory strategy and plans for FDA submission, signaling strong growth potential. Consider Adding NanoViricides, Inc. (NYSE: NNVC) To Your Radar This Morning… If you haven’t noticed yet, now could be a good time to take a look at NanoViricides, Inc. (NYSE: NNVC). With its recent move of approximately 45% in just 12 sessions, (NNVC) is turning heads, and it’s not a coincidence. With strong technicals, a market cap under $20M, and fewer than 14M shares in the float, NanoViricides, Inc. (NYSE: NNVC) is a little-known company with major potential. When you add in the fact that they’re advancing Phase 2 trials for NV-387 and receiving positive feedback from the FDA for NV-HHV-101, it’s clear this company is poised to make headlines in biotech. We have all eyes on (NNVC) this morning.  Take a look at (NNVC) while it’s still early.  After (NNVC) reached $1.55 yesterday, making a new February high, we’re continuing our coverage on this profile. In yesterday’s afternoon session, (NNVC) was triggering 17 Bullish Signals, including the Momentum Indicator Did you pull this one up yet? Keep a lookout for my next update—could be out very soon. Sincerely, Jeff Ackerman Managing Editor Stock News Trends StockNewsTrends.com (“StockNewsTrends” or “SNT” ) is owned by TD Media LLC, a single member limited liability company. Data is provided from third-party sources and StockNewsTrends is not responsible for its accuracy. Make sure to always do your own research and due diligence on any day and swing profile SNT brings to your attention. Any emojis used do not have a specific defined meaning, and may be used inconsistently. We do not provide personalized in.vest.ment advice, are not in.vest.ment advisors, and any profiles we mention are not suitable for all in.vest.ors. The owner of TD Media LLC owns and operates stocknewstrends . com (“SNT”). From time to time, SNT will publicly disseminate information about a company via website, email, SMS and other points of media. Please see important disclosure information here: stocknewstrends.com/disclosure/  *Pursuant to an agreement between TD Media LLC and Interactive Offers LLC, TD Media LLC has been hired for a period beginning on 02/17/2025 and ending on 02/21/2025 to publicly disseminate information about (NNVC:US) via digital communications. Under this agreement, TD Media LLC has been paid twenty thousand USD (“Funds”). To date, including under the previously described agreement, TD Media LLC has been paid sixty thousand USD (“Funds”). These Funds were part of the funds that TD Media LLC received from a third party who did receive the funds from the issuer and does not own stock in the issuer but the reader should assume that the clients of the third party own shares in the issuer that they will liquidate at or near the time you receive this communication, which has the potential to hurt share prices.Neither TD Media LLC or its member owns shares of (NNVC:US). Please see important disclosure information here: https://lifewatermedia.com/disclosure/nnvc/#details

TD Media LLC | 5826 New Territory Blvd. Unit #2144 | Sugar Land, TX 77479 US Unsubscribe | Update Profile | Constant Contact Data Notice